Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast

• Published in: Breast cancer research and treatment 2019-02, Vol.174 (1), p.103-111
• Main Authors: Yonekura, Rika, Osako, Tomo, Iwase, Takuji, Ogiya, Akiko, Ueno, Takayuki, Kitagawa, Masanobu, Ohno, Shinji, Akiyama, Futoshi
• Format: Article
• Language: English
• Subjects: Adjuvant chemotherapy; Biopsy; Breast cancer; Cancer; Cancer metastasis; Cancer research; Carcinoma; Comparative analysis; Ductal carcinoma in situ; Invasiveness; Lymph nodes; Lymphatic system; Medical errors; Medicine; Medicine & Public Health; Metastases; Metastasis; Oncology; Pathogenesis; Preclinical Study; Prognosis; Sectioning; Tumors
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-018-5068-4

Purpose Ductal carcinoma in situ (DCIS)—preinvasive breast cancer—with lymph node metastasis can clinically be treated as different stages: occult invasive cancer with true metastasis (T1N1) or pure DCIS with iatrogenic dissemination (TisN0). In this retrospective cohort study, we aimed to elucidate the prognostic impact and possible pathogenesis of nodal metastasis in DCIS to improve clinical management. Methods Subjects were comprised of 427 patients with routine postoperative diagnosis of DCIS who underwent sentinel node (SN) biopsy using molecular whole-lymph-node analysis. Clinicopathological characteristics and prognosis were compared between SN-positive and -negative patients. Primary tumour tissues of SN-positive patients were exhaustively step-sectioned to detect occult invasions, and predictive factors for occult invasion were investigated. Median follow-up time was 73.6 months. Results Of the 427 patients, 19 (4.4%) were SN-positive and 408 (95.6%) were SN-negative. More SN-positive patients received adjuvant systemic therapy than SN-negative patients (84.2% vs. 5.4%). Seven-year distant disease-free survivals were favourable for both cohorts (SN-positive, 100%; SN-negative, 99.7%). By examining 1421 slides, occult invasion was identified in 9 (47.4%) of the 19 SN-positive patients. Tumour burdens in SN and incidence of non-SN metastasis were similar between patients with and without occult invasion, and no predictive factor for occult invasion was found. Conclusions Node-positive DCIS has favourable prognosis with adjuvant systemic therapy. Half of the cases may be occult invasive cancer with true metastasis. In practical settings, clinicians may have to treat these tumours as node-positive small invasive cancers because it is difficult to predict the pathogenesis without exhaustive primary tumour sectioning.